about
Hyperacidification of cellubrevin endocytic compartments and defective endosomal recycling in cystic fibrosis respiratory epithelial cellsRecent advances in cystic fibrosisApplications of proteomic technologies for understanding the premature proteolysis of CFTR.CFTR trafficking and signaling in respiratory epithelium.Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis.Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.The iodide-transport-defect-causing mutation R124H: a δ-amino group at position 124 is critical for maturation and trafficking of the Na+/I- symporter.Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies.Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells.Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools.Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.Extracellular zinc and ATP restore chloride secretion across cystic fibrosis airway epithelia by triggering calcium entry.Trafficking of GFP-tagged DeltaF508-CFTR to the plasma membrane in a polarized epithelial cell line.Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3- secretion in cystic fibrosis bile ductular cells.Methoxsalen stimulates electrogenic Cl- secretion in the mouse jejunum.The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory Genistein binding site.Atypical cystic fibrosis--diagnostic and management dilemmas.
P2860
Q28216541-1EC02E35-94D3-49A7-A6C0-DAA65304BDB8Q28367361-50261A5A-20F5-4850-8624-D0D2421D9178Q34076025-39BA49D7-128E-4A97-868B-E61B13EF23D3Q34280472-AF64A23E-4566-4636-9991-AA2C0EE12BD7Q35537044-0FC85AAC-E322-4FE1-AFC5-0FC0EEF07A0AQ36615230-D9642788-7F33-4CCA-82F0-7F1082152FE1Q37061524-663E9C87-6AEC-4B31-8526-97F823A694E6Q37265316-B71653F6-5BB4-4A10-B398-B1C21D88C4AEQ38293726-C75AC47C-CF46-4EDB-AA39-C03FD0385739Q39000578-5BCF2816-011B-4BA1-B452-AE9D2BDD678CQ40399721-F82F34FA-09E0-41B8-900A-EDB9287CB1A7Q40602823-2AC7961E-213C-4FB6-B187-8FF99BE8A6FAQ40769992-ED73E5A2-DFA4-4A25-96F2-8B6EAD38889EQ42515580-57BFB913-FCAF-4A2B-8E08-522BC5EF73B0Q42686204-C9084253-EDAB-4F03-8650-F4D6EAB9917CQ44068673-26D9257E-D21B-440B-997C-5F5CE9A86721Q51659945-5B2548B5-EAA8-4087-858A-70A73C0E57FC
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Novel pharmacologic therapies for cystic fibrosis
@ast
Novel pharmacologic therapies for cystic fibrosis
@en
Novel pharmacologic therapies for cystic fibrosis.
@nl
type
label
Novel pharmacologic therapies for cystic fibrosis
@ast
Novel pharmacologic therapies for cystic fibrosis
@en
Novel pharmacologic therapies for cystic fibrosis.
@nl
prefLabel
Novel pharmacologic therapies for cystic fibrosis
@ast
Novel pharmacologic therapies for cystic fibrosis
@en
Novel pharmacologic therapies for cystic fibrosis.
@nl
P2860
P356
P1476
Novel pharmacologic therapies for cystic fibrosis
@en
P2093
P L Zeitlin
P2860
P304
P356
10.1172/JCI6346
P407
P577
1999-02-01T00:00:00Z